What is the main change in the collaboration agreement between Vertex and CRISPR?

The main change is that Vertex will now lead the global development, manufacturing, and commercialization of CTX001, with CRISPR providing support. The financial terms and profit/loss sharing have also been significantly revised.

How does the financial arrangement for CTX001 change?

Vertex will pay CRISPR an upfront $900 million and a $200 million milestone payment upon first marketing approval for CTX001. Profit and loss sharing for CTX001 will move from an equal split to 60% for Vertex and 40% for CRISPR starting July 1, 2021.

What are the 'opt-out rights' mentioned in the agreement?

Either Vertex or CRISPR can choose to exit the development of a specific product candidate at certain points. If a party opts out, they will no longer share in the profits or losses for that candidate but will instead receive a royalty percentage on its net sales.

What is the significance of the new governance structure?

The existing collaboration strategy team and working groups are being disbanded. They will be replaced by a joint oversight committee for high-level guidance and a transition committee to manage the shift in responsibilities and information sharing.

VRTX 8-K: Material Agreements

Summary

Vertex Pharmaceuticals (VRTX) has entered into an Amended and Restated Joint Development and Commercialization Agreement (A&R JDCA) with CRISPR Therapeutics AG, significantly altering the terms of their collaboration concerning CTX001TM and other product candidates. Under the new agreement, Vertex will assume leadership for global development, manufacturing, and commercialization of CTX001, with support from CRISPR. This shift in responsibility is accompanied by a revised financial structure, including an upfront payment of $900.0 million from Vertex to CRISPR and a future milestone payment of $200.0 million upon the first marketing approval of CTX001. The profit and loss sharing for CTX001 will also be adjusted, moving from an equal split to a 60/40 allocation in favor of Vertex starting from July 1, 2021, while other product candidates will maintain an equal profit and loss sharing. The A&R JDCA also introduces new governance structures, including a joint oversight committee and a transition committee, replacing previous working groups. The agreement allows for opt-out rights for either party on a candidate-by-candidate basis, with the opting-out party receiving royalties on net sales instead of sharing in profits and losses. Vertex retains the right to terminate the agreement for convenience. This revised agreement is a significant development for both companies, streamlining operations and adjusting financial contributions as they advance the development of potentially groundbreaking therapies.

Key Highlights

1Vertex assumes primary responsibility for global development, manufacturing, and commercialization of CTX001.
2Vertex will pay CRISPR an upfront payment of $900.0 million.
3Vertex will pay CRISPR an additional $200.0 million milestone payment upon the first marketing approval of CTX001.
4Profit and loss sharing for CTX001 will shift from 50/50 to 60/40 (Vertex/CRISPR) starting July 1, 2021.
5All other product candidates will continue to have net profits and losses shared equally (50/50).
6New governance structure includes a joint oversight committee and a transition committee.
7Either party can opt-out of development for specific product candidates, receiving royalties instead of profit/loss sharing.

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Apr 20, 2021)

Summary

Key Highlights

Frequently Asked Questions